34 results about "Tear secretion" patented technology

The invention belongs to the field of biological medicine, and particularly relates to a traditional Chinese medicine composition for treating xerophthalmia and relieving asthenopia and a preparation method thereof, the traditional Chinese medicine composition comprises mulberry leaf, chrysanthemum, cassia seed, wolfberry, rehmannia, dogwood, moutan bark, Chinese yam, lily, poria cocos, rhizoma alismatis, dendrobe, Chinese angelica, marigold, blueberry, lycium ruthenicum, raspberry, lutein ester and bear gall gold powder. Through the scheme, the traditional Chinese medicine composition provided by the invention can effectively treat clinical symptoms of xerophthalmia, increase tear secretion, improve fundus microcirculation and increase ciliary muscle blood flow, thereby eliminating asthenopia symptoms and improving eyesight.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of medicines for treating ophthalmic diseases. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials: flos chrysanthemi, concha haliotidis, semen cassiae torae, honey-fried licorice root and a component A, wherein the component A is selected from at least one of herba schizonepetae, radix puerariae and herba menthae. The composition has the effects of removing heat from the liver and purging heat, and treating red and astringent eye pain, and experiments show that the composition can improve the tear secretion amount, prolong the tear film rupture time and / or protect the corneal epithelium. The traditional Chinese medicine composition can be clinically used for treating dry eyes, asthenopia, keratoconjunctivitis, cataract and vitreous opacity.

The application is a divisional application of 2025116336025, the invention provides an application of 2, 4-dihydroxy-6-methoxyacetophenone in preparation of a medicine for treating lacrimal gland secretion dysfunction related diseases, a lacrimal gland dysfunction dry eye mouse model is constructed in the application, and liposome entrapped 2, 4-dihydroxy-6-methoxyacetophenone is adopted for intervention, so that the medicine for treating lacrimal gland secretion dysfunction related diseases is obtained. Experimental results show that the ocular surface function and structure of a model animal are remarkably improved through treatment of 2, 4-dihydroxy-6-methoxyacetophenone, the cornea sodium fluorescein staining score of a mouse in a 2, 4-dihydroxy-6-methoxyacetophenone treatment group is remarkably reduced, and cornea epithelium injury is effectively repaired; the epithelial structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is obviously increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. The treatment of 2, 4-dihydroxy-6-methoxyacetophenone has an improvement trend on tear film rupture time and tear secretion amount, which indicates that the 2, 4-dihydroxy-6-methoxyacetophenone has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

This invention discloses a blueberry anthocyanin nutritional solid composition for relieving eye discomfort. The composition comprises blueberry anthocyanin solid powder, algal oil powder, zinc gluconate, and selenium-enriched yeast, and may optionally contain lipid nutrients containing gamma-linolenic acid, as well as food additives and excipients. Oral administration of this composition provides the body with various nutritional supports related to ocular surface function and ocular moisture, helping to maintain tear secretion levels, improve tear film stability, and support the normal physiological state of the corneal epithelium, thereby relieving eye dryness and discomfort caused by environmental stimuli or increased eye strain. Animal experiments showed that after 14 days of continuous administration of the composition, experimental mice exhibited a significantly increased tear secretion volume compared to the control group without the composition, with an increase of approximately 165%. Corneal fluorescein staining scores were also significantly reduced, indicating improved ocular surface condition and significantly enhanced eye comfort.

The invention belongs to the technical field of medicines, and particularly relates to an active ingredient composition for treating xerophthalmia and muscae volitantes as well as a preparation method and application of the active ingredient composition. The composition is prepared from lycium barbarum polysaccharide, zeaxanthine, apigenin, luteolin, zinc gluconate, ophiopogon japonicus polysaccharide, ophiopogonin B, paeoniflorin and gallic acid according to a specific weight part ratio, all the active ingredients have a synergistic effect, the ocular surface microenvironment is improved, the vitreous opacity progress is inhibited, eye tissue damage is repaired, and the eye quality is improved. The synergistic treatment effect on the xerophthalmia and the muscae volitantes is achieved, and the symptoms such as eye dryness, eye acerbity, lacrimal secretion insufficiency, black shadow fluttering and blurred vision can be effectively relieved.

The invention relates to the technical field of intelligent health equipment, in particular to multi-mode asthenopia quantification and light-nerve regulation sleep optimization equipment which comprises an asthenopia quantification module, a light regulation module, a nerve regulation module and a central control module. The visual fatigue state is accurately quantified from multiple dimensions such as blink frequency, tear secretion, eye myoelectricity and a visual regulation function through multiple monitoring units, compared with single-index evaluation, the accuracy and comprehensiveness are greatly improved, light regulation and control and nerve regulation and control technologies are combined, and the visual fatigue state is accurately quantified. Through the synergistic effect of external visual environment optimization and internal nerve regulation, the vicious circle of asthenopia and insomnia is broken through, the intervention effect is more remarkable, personalized and intelligent regulation of light regulation and nerve regulation is achieved based on an asthenopia quantification result, the requirements of different users are met, and the user experience and the intervention effect are improved.

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The application provides an eye-care composition solution for relieving visual fatigue and a preparation method and application thereof, and belongs to the technical field of eye-care products. The composition solution comprises the following raw materials in mass percentage: Psidium guajava fruit powder 0.4-4%; Aronia melanocarpa fruit powder 0.8-4%; dihydroquercetin 0.01-0.2%; ergothioneine 0.01-0.06%; and the balance is water. The application takes Psidium guajava fruit powder and Aronia melanocarpa fruit powder as the main body, and is supplemented by dihydroquercetin and ergothioneine for joint action, so that the antioxidant and anti-inflammatory capacity of the eye can be improved, and the tear secretion of dry eye mice can be increased. The composition of the application produces a synergistic effect between the plant extracts and the high-efficiency active ingredients through scientific proportioning, aims to simultaneously relieve visual fatigue and improve dry eye symptoms, and has high product development value.

The invention provides a construction method of a mouse dry eye model, and belongs to the technical field of animal model construction. The construction method comprises the following steps: dripping a benzalkonium chloride solution into the ocular surface of a mouse, injecting a scopolamine solution into the mouse in a subcutaneous manner, placing the mouse in a dry environment, and modeling to obtain the mouse dry eye model. The formation of the mouse dry eye model is induced through a dry environment and a compound condition of benzalkonium chloride and scopolamine. According to the mouse dry eye model, the tear secretion amount is remarkably reduced, ocular surface inflammation occurs, and the dry eye syndrome can be well simulated. The model can be used for screening medicines for treating the xerophthalmia and carrying out other researches on the xerophthalmia, and has a good application prospect.

The invention discloses a traditional Chinese medicine composition capable of improving an eye regulation function, relieving eyestrain symptoms, increasing tear secretion, reducing tear inflammatory factor level and improving tear film stability, and relates to a medicine prepared by taking traditional Chinese medicines as raw materials, and the traditional Chinese medicine composition is prepared from dendrobium, semen cassiae, angelica sinensis, ligusticum wallichii, borneol, liquorice, chrysanthemum and rhizoma atractylodis. Clinical use results show that the formula has the effects of improving the eye regulation function, improving the asthenopia symptom, prolonging the tear film rupture time and increasing tear secretion, and is used for treating patients with regulation function insufficiency accompanied by dry eyes.

This invention belongs to the field of biomedicine, specifically relating to a strain of Bifidobacterium bifidum and its application in eye health products. The Bifidobacterium bifidum (… Bifidobacterium bifidum Bifidobacterium bifidum BB00, with accession number CGMCC No. 34389, is a product of this invention. It can improve the clinical symptoms of dry eye syndrome, increase tear secretion, prolong tear film breakup time, reduce ocular surface disease index, alleviate corneal epithelial damage, and regulate palpebral fissure opening. It can also regulate the composition of the intestinal flora, increase flora diversity, and inhibit the growth of pathogenic intestinal bacteria. Bifidobacterium bifidum BB00 not only provides an innovative solution to the clinical pain point of dry eye syndrome, achieving synergistic intervention between intestinal regulation and eye health, but also possesses scientific innovation, clinical effectiveness, and industrialization potential. It has significant value for the application of bacteria and bacterial agents in the biomedical field and for the treatment of ocular surface-intestinal related diseases.

The invention is a divisional application of which the application number is 2025116336025. The invention provides an application of arnica diol in preparation of a medicine for treating lacrimal gland secretion dysfunction related diseases, and relates to the technical field of biomedicine.A lacrimal gland dysfunction dry-eye mouse model is constructed, and liposome entrapped arnica diol is adopted for intervention, so that the medicine for treating lacrimal gland secretion dysfunction related diseases is obtained. Experimental results show that the ocular surface function and structure of model animals are remarkably improved through arnica glycol treatment, the sodium corneal fluorescein staining score of mice in an arnica glycol treatment group is remarkably reduced, and corneal epithelium injuries are effectively repaired; the epithelial structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is obviously increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. And the arnica glycol treatment has an improvement trend on tear film rupture time and tear secretion volume, which indicates that the arnica glycol has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

A novel humectant eye drop composition is disclosed. The composition comprises a synergistic combination of nicotinamide and adenosine in concentrations at which neither component is effective individually. In preferred embodiments of the invention, the composition comprises 0.025% (w / v) and 0.05% (w / v) nicotinamide. Within 2 - 3 weeks of commencement of application, the composition improves the Tear Film Breakup Time, improves tear production as measured by the Schirmer Test, reduces the severity of the Dry Eye Syndrome as measured by Lissamine Green staining, and shows anti-inflammatory effects.

The invention belongs to the technical field of functional feed additives for pets, and discloses a selenium-enriched yeast additive for relieving tear stains of pets, the additive takes selenium-enriched yeast as a core effective component, the content of organic selenium in the selenium-enriched yeast is not less than 1000 mg / kg, and the content of organic selenium in the selenium-enriched yeast is not less than 1000 mg / kg. The chrysanthemum extract, the honeysuckle flower extract and the semen cassiae extract are compounded to form an anti-inflammatory heat-clearing component which is used for relieving lacrimal gland inflammation reaction and reducing abnormal tear secretion; meanwhile, L-lysine, taurine, vitamin C and xanthophyll are introduced as nutrition synergistic components, so that the lacrimal gland mucosa conditioning and eye protection effects are enhanced. According to the additive, low-sodium and low-iodine carrier raw materials are further adopted, and a micronization dispersion treatment process is combined, so that the uniformity and palatability of the product in pet feed are improved. Through multiple synergistic effects of antioxidation, anti-inflammation, heat clearing and nutrition regulation, the pet feed can effectively relieve tear stains of pets from the level of nutrition regulation, and is suitable for long-term feeding of pets.

The application is a divisional application of 2025116336025, the invention provides an application of diserpine in preparation of drugs for treating lacrimal gland secretion dysfunction related diseases, and the technical key points are as follows: in the application, a lacrimal gland dysfunction dry eye mouse model is constructed, and lipidosome entrapped diserpine is adopted for intervention. Through comprehensive analysis of multiple physiological and histological indexes, the ocular surface function and structure of the model animal are remarkably improved through diserine treatment. Specifically, compared with a model control group, the corneal fluorescein sodium staining score of mice in a diserine treatment group is remarkably reduced, which indicates that the corneal epithelium injury is effectively repaired; meanwhile, the epithelium structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is also remarkably increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. And the diserpine treatment has an improvement trend on tear film rupture time and tear secretion volume, which indicates that the diserpine has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

The invention relates to the technical field of compounds, in particular to an aesculetin derivative, a preparation method of the aesculetin derivative and application of the aesculetin derivative in preparation of drugs for preventing and treating xerophthalmia. According to the aesculetin derivative disclosed by the invention, the water solubility is improved on the basis of an aesculetin mother nucleus. System safety evaluation shows that the ocular surface cytotoxicity is obviously lower than that of a prototype, no obvious cell injury or apoptosis is caused within an effective treatment concentration, and no obvious adverse reaction is caused in a systemic toxicity test. In an animal dry eye model, the derivative has better effects of increasing tear secretion, prolonging tear film rupture time, reducing cornea staining score, improving symptoms and repairing ocular surface injury than existing drugs, and takes effect faster.

The application provides application of KGF-2 in treatment of dry eye, and proves that KGF-2 can improve the basic tear secretion of dry eye mice in a dose-dependent manner, prolong the tear film break-up time, reduce the corneal epithelium and corneal nerve injury, and can reduce the expression levels of inflammatory factors such as tear gland MMP-3, MMP-9 and TNF alpha, and improve the tear secretion function of the tear gland.

The present invention relates to the technical field of liquid collection, and in particular to a tear secretion volume acquisition method and system. The method comprises: collecting a tear meniscus image of a subject; using a motion sensor and an image recognition algorithm to track the flowing of a tear meniscus in real time; processing the collected tear meniscus image; calculating a tear meniscus height value; performing analysis on the basis of received image data, and determining whether the tear meniscus height value is normal; and a user checking real-time data and historical records of the tear meniscus height value by means of a touch screen, and performing system setting and parameter adjustment by means of control buttons. In the present invention, a motion sensor and an advanced image recognition algorithm are combined, such that a flowing path of a tear meniscus can be recognized and tracked in real time. Such an integrated application makes a dynamic tracking process more accurate, can effectively cope with complex changes in morphology and flowing of a tear meniscus, and updates images in real time and performs error correction. The present invention improves the tracking precision and system response speed, enabling more real-time and accurate monitoring of the flowing of a tear meniscus.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a composition for treating dry eyes and a preparation method thereof.The composition is prepared from 55-65 parts of mineral ion solution, 20-30 parts of plant active extract, 4-6 parts of osmotic pressure regulator and 3-5 parts of PH stabilizer. The preparation method of the composition for treating the dry eye comprises the following steps: adding the plant active extract into the mineral ion solution, uniformly mixing, adding the osmotic pressure regulator and the pH stabilizer, uniformly stirring, and sterilizing under high pressure to obtain the composition for treating the dry eye. The tear film stability is enhanced; corneal epithelium injury is relieved, and corneal fluorescein staining is negative after treatment; the lacrimal amount can be increased, the condition of slight abnormal lacrimal secretion is improved, and the treatment effect on the dry eye is remarkable.

The application belongs to the technical field of medicine preparation, and particularly relates to a TRPM8 agonist compound and a preparation method and application thereof. The deuterated TRPM8 agonist compound provided by the application has excellent TRPM8 receptor agonist activity, can effectively improve the symptoms of dry eye, significantly promote tear secretion and repair corneal epithelial damage, and has better curative effect than existing classical TRPM8 agonists, and can be used for preparing a medicine for treating dry eye, thereby providing a new effective selection for clinical treatment of dry eye. The deuterated TRPM8 agonist compound provided by the application is prepared by using a four-step synthesis process, raw materials are easy to obtain, process operation is simple, and the reaction process is stable and controllable, and is suitable for industrialized synthesis.

The invention discloses a preparation method of eyedrops for preventing eye injury, and belongs to the technical field of eyedrops, the eyedrops are prepared by taking rhizoma polygonati, herba houttuyniae, sodium chloride, ethylparaben, distilled water and hypertonic liquid as raw materials, and the hypertonic liquid prepared by mixing glucose injection and vitamin C injection in the eyedrops has a dehydration effect in the application process, so that the eye injury can be prevented. The corneal edema can be quickly eliminated, the dehydration of corneal tissues is promoted, and the normal thickness is recovered, so that the vision is quickly recovered, the damage of corneal endothelium is furthest reduced, the corneal edema in the treatment process is effectively reduced, and the probability of cataract is further reduced; according to the traditional Chinese medicine eye drop, the components of rhizoma polygonati and herba houttuyniae are added, so that the eye drop has antibacterial and antiviral effects, rhizoma polygonati polysaccharide contained in rhizoma polygonati has the effects of increasing tear secretion and promoting ocular surface healing, dry eyes, foreign body sensation and burning sensation are improved, and the eye drop has no obvious irritation to cornea and iris and is suitable for different people.

This invention discloses the application of necrotizing 1 (Necrostatin-1) in the preparation of drugs for the prevention and / or treatment of dry eye, relating to the field of biomedical technology. The application of necrotizing 1 in the preparation of drugs for the prevention and / or treatment of dry eye is described. This invention is the first to discover the application of the programmed necrosis inhibitor Necrostatin-1 in the treatment of dry eye. Nec-1, by inhibiting programmed necrosis, can effectively protect corneal epithelial cells and reduce ocular surface inflammation and damage. In a scopolamine-induced dry eye model, subconjunctival injection of 0.3 μM Nec-1 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, without significant drug toxicity. Nec-1 provides a new targeting strategy for dry eye treatment and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention provides an application of a chrysanthemum exosome, one is an application of the chrysanthemum exosome in preparation of a medicine for treating xerophthalmia, the chrysanthemum exosome is adopted as an active preparation, and the chrysanthemum exosome can play a preventive protection role before the xerophthalmia occurs and effectively maintain a tear secretion level so as to improve an ocular surface structure and a functional state; meanwhile, the exosome is natural in source and good in biocompatibility, the stability and bioavailability of active ingredients of chrysanthemum are improved, the safety risk possibly caused by high-dose use of traditional extracts is reduced, and the exosome is suitable for long-term or repeated administration and has a good application prospect in prevention and adjuvant therapy of xerophthalmia. Secondly, the chrysanthemum exosome is applied to preparation of anti-inflammatory drugs and non-treatment in macrophage immunoregulation activity, various components in the chrysanthemum exosome can target a plurality of key targets in an inflammation pathway through a synergistic effect, a multi-dimensional anti-inflammatory network is formed, and the chrysanthemum exosome has excellent anti-inflammatory application potential.

The invention discloses a copper ion-sargentgloryvine stem carbon quantum dot nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: mixing copper ions, sargentgloryvine stem and water, performing hydrothermal reaction, and centrifuging to obtain supernate; and carrying out filtration treatment, dialysis treatment and drying treatment on the supernate to obtain the copper ion-sargentgloryvine stem carbon quantum dot nano-enzyme. The nano-enzyme can obviously improve corneal injury caused by xerophthalmia, prolong tear film rupture time, increase tear secretion amount and obviously reduce the ROS level of corneal tissue, is high in ocular surface retention capacity and has no toxicity to important organs such as heart, liver and spleen. Compared with positive control drug sodium hyaluronate eye drops, the nano-enzyme has the advantages of inflammation resistance, oxidation resistance and biological safety, provides a novel and efficient treatment strategy for xerophthalmia treatment, and has a wide application prospect.

The invention belongs to the technical field of marine natural product extraction and biological medicine, and particularly relates to a preparation method of fucoxanthin and application of the fucoxanthin to preparation of a product with the effect of relieving xerophthalmia. The fucoxanthin disclosed by the invention is prepared by the following steps: crushing cleaned and dried seaweed, performing alcohol extraction, extracting and purifying to obtain a fucoxanthin product. The method has the beneficial effects that the purity of the fucoxanthin prepared by adopting the method disclosed by the invention is higher, in-vivo and in-vitro experiments prove that the extracted fucoxanthin has the effect of relieving the tear secretion deficiency type xerophthalmia, and a new raw material source and theoretical support are provided for treating the xerophthalmia.

The invention provides a coordinate axis organ-like chip for high-throughput in-situ tracking drug screening and a construction method thereof, relates to the technical field of biomedicine, and is technically characterized by comprising lacrimal gland organ culture, organ-like chip construction and drug screening platform construction. According to the platform, lacrimal gland organs are used for simulating human lacrimal gland secretion, in-situ tracking of bright field pictures of the organs is achieved based on a uniquely-designed organ-like chip, an intelligent big data analysis system and an intelligent robot arm are used as assistants, high-throughput screening is conducted on an MCE traditional Chinese medicine monomer database (TCMMD), and a traditional Chinese medicine monomer database is obtained. And effective screening of the traditional Chinese medicine monomers for promoting lacrimal gland tear secretion is realized. Besides, the invention further provides traditional Chinese medicine monomers obtained through screening based on the platform, the traditional Chinese medicine monomers comprise diserpine, 2, 4-dihydroxy-6-methoxyacetophenone, 9 '-salvianolic acid B monomethyl ester, ammonium glycyrrhizinate and arnica glycol, and a new thought and method are provided for treating lacrimal gland secretion dysfunction related diseases.

The present application relates to the technical field of sign data processing, in particular to a visual impairment personalized protection method and system based on tear secretion monitoring. The regional physiological signals of a user are acquired; the eyelid activity signals are processed to extract incomplete blinking features, and the incomplete blinking rate is calculated based on the incomplete blinking features; the tear dynamic signals are processed to extract tear secretion indicators; the personalized physiological baseline corresponding to the user is constructed, and the personalized physiological baseline, the incomplete blinking rate and the tear secretion indicators are compared to obtain baseline difference information; the baseline difference information is input into an impairment risk prediction model to obtain a visual impairment risk coefficient, and in response to the visual impairment risk coefficient reaching a preset threshold, a corresponding protection intervention instruction is triggered. The present application can provide a personalized, accurate and good experience visual protection scheme for the user.

In various implementations, a device for stimulating the lacrimal gland and optionally the meibomian gland of an eye of a user by emitting light on the retina may include a control unit and an optical system connected to the control unit and arranged in the viewing direction of the user. The optical system may include at least one light source and may be configured for providing light stimulation pulses to an eye of the user by the at least one light source. Implementations of the device may also include a power supply unit for supplying power to the control unit and / or optical system. The light stimulation pulses activate the pupillary light reflex and one or more reflexes selected from blink reflex, corneal reflex, menace reflex, and lacrimal reflex. When the device is in operation mode a light intensity gradient between the light pulses emitted by the at least one light source and the light around the eye may be maintained at 2 or more lumens. The light stimulation pulses may induce blinking of the eye of the user.

This application provides an eye drop containing peceganam-modified hyaluronic acid, its preparation method, and its application. The eye drop is prepared using peceganam-modified hyaluronic acid, adipose-derived mesenchymal stem cell exosomes, and physiological saline. This eye drop exhibits good wetting and antibacterial properties, is non-toxic, has no side effects, and does not induce drug resistance. It can effectively repair damaged ocular cells, promote tear secretion, and facilitate rapid recovery from dry eye disease.